The superior safety of the vector vaccine with the new promoter will be confirmed, which will allow us to submit a new patent application for this vector promoter combination. In addition, another foreign viral gene will be introduced to prove the ease with which a new vaccine can be made. The PCV2 capsular protein was selected because PCV2 vaccines are widely used worldwide and are very difficult to make, making them very expensive. With the new vector vaccine we want to produce large quantities of viral proteins at a low cost. In a subsequent experiment we want to demonstrate that in addition to an active, passive immunity is also induced. If successful, this will increase the interest of pharmaceutical companies. During the project, we also want to unravel the mechanism for the difference in safety between the two promoters. An answer to this question will not only help us to write a patent application but can also help us improve the vaccine.